Related Experiment Video
Updated: Jun 9, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Raf-1 kinase inhibitory protein expression in thyroid carcinomas
Hyun-Soo Kim1, Gou Young Kim, Sung-Jig Lim
1Department of Pathology, Graduate School of Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, 130-702 Seoul, Republic of Korea.
Endocrine Pathology
|August 25, 2010
Summary
Raf-1 kinase inhibitory protein (RKIP) is strongly expressed in most thyroid carcinomas but is absent in anaplastic thyroid carcinoma. This significant reduction in RKIP protein levels highlights its potential role in anaplastic thyroid cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Raf-1 kinase inhibitory protein (RKIP) is involved in crucial cellular processes like growth, differentiation, and apoptosis.
- Reduced RKIP expression is observed in various human carcinomas, but its role in thyroid cancer remains uninvestigated at the protein level.
Purpose of the Study:
- To investigate the protein expression of RKIP across different subtypes of thyroid carcinoma using immunohistochemistry.
- To compare RKIP expression in primary tumors versus nodal metastatic lesions.
Main Methods:
- Immunohistochemical staining for RKIP was performed on 104 primary thyroid carcinoma samples (papillary, follicular, medullary, poorly differentiated, and anaplastic) and 26 nodal metastatic tumors.
- Quantitative and qualitative analysis of RKIP cytoplasmic immunoreactivity was conducted.
Main Results:
- Strong and uniform RKIP expression was observed in normal thyroid tissue, papillary, follicular, and medullary carcinomas.
- Poorly differentiated carcinomas generally showed strong RKIP expression, with one exception.
- RKIP expression was completely absent in all anaplastic thyroid carcinomas, a statistically significant finding (P < 0.0001).
- Metastatic anaplastic carcinomas also lacked RKIP expression, mirroring primary tumor findings.
Conclusions:
- RKIP expression is significantly reduced or absent in anaplastic thyroid carcinoma compared to other thyroid cancer subtypes.
- The loss of RKIP may be a key event in the progression of differentiated thyroid carcinoma to anaplastic thyroid carcinoma.
- Further research is needed to understand RKIP's specific function and therapeutic potential in anaplastic thyroid cancer.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...